X4 Pharmaceuticals, Inc (XFOR) stock
XFORNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$3.09+0.26 (+9.19%)
Close on Nov 17, 2026Market cap $306.36MP/E –Yield –
X4 Pharmaceuticals r&d expenses
Research and development expenses are spending on new products and technology.
X4 Pharmaceuticals's R&D Expenses for the twelve months ending Sep 30, 2026 was $62.39M, down 17.8% year over year. For fiscal 2025 it was $72.72M, down 10.9% from the year before. The highest annual figure on record is $81.64M in fiscal 2024.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $72.72M | -10.9% |
| FY2024 | Dec 31, 2024 | $81.64M | +13.4% |
| FY2023 | Dec 31, 2023 | $72.02M | +17.9% |
| FY2022 | Dec 31, 2022 | $61.06M | +20.6% |
| FY2021 | Dec 31, 2021 | $50.65M | +20.8% |
| FY2020 | Dec 31, 2020 | $41.93M | +39.0% |
| FY2019 | Dec 31, 2019 | $30.16M | +48.3% |
| FY2018 | Dec 31, 2018 | $20.35M | +19.2% |
| FY2017 | Dec 31, 2017 | $17.07M | -4.3% |
| FY2016 | Dec 31, 2016 | $17.83M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $13.34M | -23.0% |
| Q2 FY2026 | Jun 30, 2026 | $15.08M | -17.8% |
| Q1 FY2026 | Mar 31, 2026 | $15.45M | -16.5% |
| Q4 FY2025 | Dec 31, 2025 | $18.52M | -14.7% |
| Q3 FY2025 | Sep 30, 2025 | $17.34M | -9.6% |
| Q2 FY2025 | Jun 30, 2025 | $18.35M | -12.3% |
| Q1 FY2025 | Mar 31, 2025 | $18.51M | -6.8% |
| Q4 FY2024 | Dec 31, 2024 | $21.70M | +39.1% |
| Q3 FY2024 | Sep 30, 2024 | $19.17M | -13.1% |
| Q2 FY2024 | Jun 30, 2024 | $20.91M | +10.0% |
| Q1 FY2024 | Mar 31, 2024 | $19.85M | +40.7% |
| Q2 FY2023 | Jun 30, 2023 | $15.60M | +12.9% |
| Q1 FY2023 | Mar 31, 2023 | $22.06M | +56.3% |
| Q4 FY2022 | Dec 31, 2022 | $19.01M | +56.3% |
| Q3 FY2022 | Sep 30, 2022 | $14.11M | +7.0% |
| Q2 FY2022 | Jun 30, 2022 | $13.82M | +4.8% |
| Q1 FY2022 | Mar 31, 2022 | $14.11M | +16.6% |
| Q4 FY2021 | Dec 31, 2021 | $12.16M | -1.1% |
| Q3 FY2021 | Sep 30, 2021 | $13.19M | +15.9% |
| Q2 FY2021 | Jun 30, 2021 | $13.19M | +41.2% |
| Q1 FY2021 | Mar 31, 2021 | $12.10M | +35.8% |
| Q4 FY2020 | Dec 31, 2020 | $12.30M | +74.1% |
| Q3 FY2020 | Sep 30, 2020 | $11.38M | +32.5% |
| Q2 FY2020 | Jun 30, 2020 | $9.34M | +5.5% |
| Q1 FY2020 | Mar 31, 2020 | $8.91M | +57.6% |
| Q4 FY2019 | Dec 31, 2019 | $7.07M | +50.7% |
| Q3 FY2019 | Sep 30, 2019 | $8.59M | +39.5% |
| Q2 FY2019 | Jun 30, 2019 | $8.85M | +86.2% |
| Q1 FY2019 | Mar 31, 2019 | $5.66M | +19.2% |
| Q4 FY2018 | Dec 31, 2018 | $4.69M | -49.2% |
| Q3 FY2018 | Sep 30, 2018 | $6.16M | -41.9% |
| Q2 FY2018 | Jun 30, 2018 | $4.76M | +21.7% |
| Q1 FY2018 | Mar 31, 2018 | $4.74M | +8.0% |
| Q4 FY2017 | Dec 31, 2017 | $9.23M | – |
| Q3 FY2017 | Sep 30, 2017 | $10.60M | – |
| Q2 FY2017 | Jun 30, 2017 | $3.91M | – |
| Q1 FY2017 | Mar 31, 2017 | $4.39M | – |
See a number that looks wrong?